NXTMH.HE
SellFallen FavouriteNexstim Plc · Healthcare · Finland · $79M · Avg Vol: $77K/d
Fallen Favourite: A good business that is expensive and falling. Wait for the price to catch up.
ABOUT NEXSTIM PLC
Read
Nexstim Plc is a medical technology company specializing in personalized, non-invasive brain stimulation technologies for the treatment of major depression and chronic pain. Its competitive moat is anchored by its proprietary Navigated Brain Therapy and Navigated Transcranial Magnetic Stimulation systems, which offer unique 3D brain imaging integration. It operates as a niche, high-growth medical device player in the neuromodulation market.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.5M | 7.2M | 8.7M | 11.0M | 4.8% | 11.8M | 13.3M | 15.5M | 19.1% |
| EPS (EUR) | 0.20 | -0.20 | -0.13 | 0.08 | -26.3% | 0.01 | 0.13 | 0.27 | 83.7% |
| Shares | 6.7M | 6.8M | 7.2M | 7.2M | +7.4% | 7.2M | — | — | — |
| Debt | 3.5M | 4.4M | 5.4M | 4.1M | 5.8% | 3.4M | — | — | — |
| Equity | 4.1M | 2.8M | 3.7M | 4.2M | 0.9% | — | — | — | — |
| Op CF | 1.0M | -2.3M | 1.9M | 1.7M | 18.5% | 1.2M | — | — | — |
| Inv CF | -1.4M | -1.7M | -2.0M | -1.7M | — | — | — | — | — |
| Fin CF | -0.4M | 1.0M | 2.5M | -1.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NXTMH.HE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NXTMH.HE | Nexstim Plc(you) | $79M | 27 | Sell |
| MODU.HE | Modulight Oyj | $51M | 32 | Sell |
| REG1V.HE | Revenio Group Oyj | $435M | 44 | Hold |
| NANOFH.HE | Nanoform Finland Oyj | $86M | 31 | Sell |
| OPTOMED.HE | Optomed Oyj | $59M | 16 | Strong Sell |
| HEALTH.HE | Nightingale Health Oyj | $65M | 13 | Strong Sell |
| FARN.L | Faron Pharmaceuticals Oy | $95M | 7 | Strong Sell |
| AIFORIA.HE | Aiforia Technologies Oyj | $74M | 3 | Strong Sell |
| HRTIS.HE | Herantis Pharma Oyj | $51M | 5 | Strong Sell |
| ORIOLA.HE | Oriola Oyj | $191M | 67 | Buy |
Peer medians: ROE -19.1% · P/E 17.0x · Gross margin 65.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.